177Lu-DOTATATE shows efficacy in both grade 2 high and grade 3 low GEP-NETs
Promising data from a subgroup analysis of the phase III NETTER-2 study support the use of peptide receptor radionuclide therapy in treatment-naïve patients
A new combination treatment shows early promise in GEP-NECs
Lurbinectedin and irinotecan demonstrate a synergic clinical effect in patients with neuroendocrine carcinomas of gastroenteropatic primary site after chemotherapy failure
Promising advances in the molecular landscape of NETs
Molecular genetic analyses of NETs hint at actionable therapeutic targets and potential predictive biomarkers of response to axitinib
Molecular profiling of neuroendocrine neoplasms reveals markers with prognostic and therapeutic relevance
A Spanish study describes the genomic characterisation of neuroendocrine neoplasms as the first step towards more personalised management
The first randomised study of peptide receptor radionuclide therapy in pancreatic NETs met its primary endpoint
In the OCLURANDOM trial, progression-free survival was longer in patients receiving lutetium-octreotate versus sunitinib
NECs: mixed results for second-line therapy after progression
The optimal chemotherapy regimen in this setting is not well-defined
Rare NETs: sunitinib shows efficacy in pheochromocytoma and paraganglioma
Practice-changing results were also presented in bronchopulmonary and non-pancreatic NETs with somatostatin analogues and VEGFR inhibitors
Can immunotherapy improve the treatment of advanced neuroendocrine neoplasms?
Latest findings on the use of single-agent and combination immunotherapy are not conclusive, despite being promising